IL15 and prostate cancer: In addition to IL-15, which has been considered a promising immunotherapeutic agent to treat prostate cancer due to its ability to activate immune cells, in particular NK cells (19), the ADU-S100 analog 2’3’-c-di-AM(PS)2 (Rp,Rp) was also chosen due to its ability to stimulate type I interferon (IFN) expression in immune cells and convert cold tumors into immunologically hot tumors in some models of solid tumors (36, 37).